|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
NLM197038913 |
003 |
DE-627 |
005 |
20250211103828.0 |
007 |
cr uuu---uuuuu |
008 |
231223s2010 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.2144/000113352
|2 doi
|
028 |
5 |
2 |
|a pubmed25n0657.xml
|
035 |
|
|
|a (DE-627)NLM197038913
|
035 |
|
|
|a (NLM)20359294
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Pfannkuche, Kurt
|e verfasserin
|4 aut
|
245 |
1 |
2 |
|a A Cre-based double fluorescence indicator system for monitoring cell fusion events and selection of fused cells
|
264 |
|
1 |
|c 2010
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 28.06.2010
|
500 |
|
|
|a Date Revised 13.12.2023
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a We have established an in vitro Cre/loxP-based assay for monitoring cell fusion events that specifically traces the transport of cytoplasm from one cell to its fusion partner. Cells with a double fluorescence vector indicate fusion with cells expressing Cre recombinase by switching expression from red to green fluorescent protein through a Cre-mediated recombination event that simultaneously activates puromycin-acetyltransferase expression. This strategy allows for both the observation and puromycin selection of indicator cells that have undergone fusion with a Cre recombinase-expressing partner. A fusion protein of Cre with estrogen receptor (ER) can be used to control Cre recombinase activity through the tamoxifen-induced translocation of the Cre-ER fusion protein to the nucleus. Here we have established a new methodology that not only allows the monitoring of the transport of cellular contents, but also enables the purification of fused cells using puromycin
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
7 |
|a Luminescent Proteins
|2 NLM
|
650 |
|
7 |
|a Receptors, Estrogen
|2 NLM
|
650 |
|
7 |
|a Puromycin
|2 NLM
|
650 |
|
7 |
|a 4A6ZS6Q2CL
|2 NLM
|
650 |
|
7 |
|a Cre recombinase
|2 NLM
|
650 |
|
7 |
|a EC 2.7.7.-
|2 NLM
|
650 |
|
7 |
|a Integrases
|2 NLM
|
650 |
|
7 |
|a EC 2.7.7.-
|2 NLM
|
700 |
1 |
|
|a Spitkovsky, Dimitry
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Wunderlich, Frank Thomas
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Abd El Aziz, Osama Mohamed
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Saric, Tomo
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Hescheler, Jürgen
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Sachinidis, Agapios
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t BioTechniques
|d 1993
|g 48(2010), 2 vom: 01. Feb., Seite 113-20
|w (DE-627)NLM012627046
|x 1940-9818
|7 nnns
|
773 |
1 |
8 |
|g volume:48
|g year:2010
|g number:2
|g day:01
|g month:02
|g pages:113-20
|
856 |
4 |
0 |
|u http://dx.doi.org/10.2144/000113352
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_21
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_50
|
912 |
|
|
|a GBV_ILN_60
|
912 |
|
|
|a GBV_ILN_62
|
912 |
|
|
|a GBV_ILN_65
|
912 |
|
|
|a GBV_ILN_70
|
912 |
|
|
|a GBV_ILN_99
|
912 |
|
|
|a GBV_ILN_121
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_227
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_618
|
912 |
|
|
|a GBV_ILN_640
|
912 |
|
|
|a GBV_ILN_754
|
912 |
|
|
|a GBV_ILN_2001
|
912 |
|
|
|a GBV_ILN_2002
|
912 |
|
|
|a GBV_ILN_2003
|
912 |
|
|
|a GBV_ILN_2005
|
912 |
|
|
|a GBV_ILN_2006
|
912 |
|
|
|a GBV_ILN_2007
|
912 |
|
|
|a GBV_ILN_2008
|
912 |
|
|
|a GBV_ILN_2009
|
912 |
|
|
|a GBV_ILN_2010
|
912 |
|
|
|a GBV_ILN_2012
|
912 |
|
|
|a GBV_ILN_2015
|
912 |
|
|
|a GBV_ILN_2018
|
912 |
|
|
|a GBV_ILN_2023
|
912 |
|
|
|a GBV_ILN_2035
|
912 |
|
|
|a GBV_ILN_2040
|
912 |
|
|
|a GBV_ILN_2060
|
912 |
|
|
|a GBV_ILN_2099
|
912 |
|
|
|a GBV_ILN_2105
|
912 |
|
|
|a GBV_ILN_2121
|
912 |
|
|
|a GBV_ILN_2470
|
951 |
|
|
|a AR
|
952 |
|
|
|d 48
|j 2010
|e 2
|b 01
|c 02
|h 113-20
|